Strides Acrolab Breaks Ground on Malaysian Biomanufacturing Facility
STELIS Biopharma, a subsidiary of Strides Acrolab, has broken ground for a biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia. Bio-XCell had previously announced the signing of a build and lease agreement with Bio-XCell for the construction of the building and part of the equipment of STELIS Biopharma's 140,000 square-foot biologics facility, for a total project investment amount of RM 201 million. ($60 million).
STELIS Biopharma (Malaysia) Sdn. Bhd., the Strides subsidiary constructing this facility, will manufacture and commercialize its internal and partnered pipeline of biopharmaceuticals as well as provide contract manufacturing services and clinical supplies. At peak operations, the facility will employ 180 people in R&D, manufacturing, QA/QC, analytical, and regulatory operations.
The construction and fit-out of the facility is expected to be completed in 24 months and commercial operations are targeted to begin mid-2017 at Bio-XCell Park. The 140,000-square foot facility will incorporate single-use bio-processing technology with both mammalian and microbial manufacturing suites. The facility will also house an R&D unit to conduct scale-up and process development studies.
Source: Strides Acrolabs